press center press release

ZS Pharma, Inc. (Nasdaq: ZSPH) to Ring The Nasdaq Stock Market Opening Bell




ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, will visit the Nasdaq MarketSite in Times Square. The Company’s initial focus is on the development of ZS-9, a product candidate in Phase 3 development for the treatment of hyperkalemia.

In honor of the occasion, Robert Alexander, Ph.D., Chief Executive Officer will ring the Opening Bell.


Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio


Monday, December 15, 2014 – 9:15 a.m. to 9:30 a.m. ET

ZS Pharma, Inc. Media Contact:

Denise Powell

(510) 703-9491

Nasdaq MarketSite:

Christine Barna

(646) 441-5310

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0


Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

For photos from ceremonies and events visit our Instagram Page:

For news tweets, please visit our Twitter page at:

For exciting viral content and ceremony photos visit Tumblr Page:


A webcast of the Nasdaq Opening Bell will be available at: or


To obtain a hi-resolution photograph of the Market Open, please go to and click on the market open of your choice.

About ZS Pharma, Inc. (Nasdaq:ZSPH):

ZS Pharma is a publicly-traded, specialty pharmaceutical company based in Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9, is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information is available at

The Company’s initial focus is on the development of ZS-9, a product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood and is a potentially life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. Hyperkalemia can also arise from the use of RAAS inhibitors, which are commonly prescribed for patients with hypertension, heart failure and CKD. Currently there is a lack of effective, safe and tolerable treatments for hyperkalemia.

The Company recently completed a Phase 3 clinical trial, HARMONIZE, that over a longer treatment period, confirmed the positive results from its first Phase 3 clinical trial, ZS003. With two Phase 3 trials completed and additional long-term safety studies, ZS004E and ZS005, underway, the Company plans to file a New Drug Application (NDA) with the United States Food and Drug Administration and a Marketing Authorization Application (MAA) with the European Medicines Agency in the first half of 2015.

In June of this year, ZS Pharma closed its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit or


In This Story


Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more